Compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system
Described are novel salts of the compound (3R,4R,5S)-5-(difluoromethyl) piperidine-3,4-diol, as well as methods of using the same for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system. In particular, the present invention provides methods for preventing and/or treating Gaucher's disease and/or Parkinson's disease.
1. A tosylate salt of (3R,4R,5S)-5-(difluoromethyl)piperidine-3,4-diol with a melting point in the range of about 174.9° C. to about 178.2° C.
2. The tosylate salt of claim 1 , wherein the tosylate salt has a peak melting point of about 176.5° C.
3. A crystalline form of a tosylate salt of (3R,4R,5S)-5-(difluoromethyl)piperidine-3,4-diol having an X-ray diffraction pattern comprising characteristic peaks at:
2-Theta (Degrees)
17.38 ± 0.2
17.74 ± 0.2
20.18 ± 0.2
23.74 ± 0.2
25.22 ± 0.2.
4. The crystalline form of claim 3 , wherein the X-ray diffraction pattern further comprises characteristic peaks at:
2-Theta (Degrees)
9.34 ± 0.2
18.70 ± 0.2
19.58 ± 0.2
20.62 ± 0.2.
5. The crystalline form of claim 4 , wherein the X-ray diffraction pattern further comprises characteristic peaks at:
2-Theta (Degrees)
16.14 ± 0.2
21.62 ± 0.2
26.18 ± 0.2
28.22 ± 0.2.
6. A crystalline form of a tosylate salt of (3R,4R,5S)-5-(difluoromethyl)piperidine-3,4-diol, wherein the tosylate salt comprises a crystalline form having an X-ray diffraction pattern of FIG. 3 .